"全程绿灯"加速好药上市步伐 今年8月，《中国（江苏）自由贸易试验区生物医药全产业链开放创新发展方案》获得国务院批复并正 式发布。9月16日，省政府召开新闻发布会，深度解读该方案背后的"首创性"与"集成性"，以3个关键词 勾勒出江苏生物医药产业开放创新的新蓝图：从实验室研发到临床使用全流程加速，让"好药"研发、通 关、使用环节实现"全程绿灯"；从全球高端人才到跨境数据资源自由流通，让百姓在家门口就能挂上外 籍专家号……这场覆盖全链条的改革实践，让"江苏造"创新药离市场更近，更快造福患者，折射民生温 度。 该方案以问题为导向，在流程效率、资源配置、创新生态等关键领域实现突破性进展，让政策红利真正 看得见、摸得着、用得上。 "方案自酝酿之初，就坚持以解决企业的困难诉求为制度创新的出发点和突破口。文件的起草过程，就 是帮助企业解决问题的过程。"司勇举例说，方案第9条"进出境实验动物监管模式改革"便源于企业困 境。省内一家基因工程小鼠企业，其携带人类基因的实验小鼠是新药研发关键模型动物，因携带人类遗 传物质，此前需接受特殊物品与实验动物出口双重监管，通关耗时久。但小鼠生命周期短，常未完成监 管就长成成年鼠，丧失实验价 ...

□ 本报记者 王梦然 今年8月，《中国（江苏）自由贸易试验区生物医药全产业链开放创新发展方案》获得国务院批复并正 式发布。9月16日，省政府召开新闻发布会，深度解读该方案背后的"首创性"与"集成性"，以3个关键词 勾勒出江苏生物医药产业开放创新的新蓝图：从实验室研发到临床使用全流程加速，让"好药"研发、通 关、使用环节实现"全程绿灯"；从全球高端人才到跨境数据资源自由流通，让百姓在家门口就能挂上外 籍专家号……这场覆盖全链条的改革实践，让"江苏造"创新药离市场更近，更快造福患者，折射民生温 度。 三大关键词锚定"全链创新" 该方案以"全链条改革、制度型开放、高水平创新"为核心骨架，系统构建起覆盖生物医药产业研发、生 产、流通、使用全周期的创新体系，每个关键词都精准破解产业发展痛点。 "一条链的改革，贯通6个方面18项政策集成。"省商务厅厅长司勇介绍，方案从增强研发创新能力、提 升审批服务水平、构建生产流通体系、完善采购使用政策、加大要素保障、守牢安全底线6个方面，细 化18项举措，核心目标是为国家探制度、为江苏赋动能、为企业解难题。 "全链条改革"立足优势精准破局。江苏生物医药产业规模占全国1/8，创新药获批 ...

今年8月，《中国（江苏）自由贸易试验区生物医药全产业链开放创新发展方案》获得国务院批复 并正式发布。9月16日，省政府召开新闻发布会，深度解读该方案背后的"首创性"与"集成性"，以3个关 键词勾勒出江苏生物医药产业开放创新的新蓝图：从实验室研发到临床使用全流程加速，让"好药"研 发、通关、使用环节实现"全程绿灯"；从全球高端人才到跨境数据资源自由流通，让百姓在家门口就能 挂上外籍专家号……这场覆盖全链条的改革实践，让"江苏造"创新药离市场更近，更快造福患者，折射 民生温度。 三大关键词锚定"全链创新" 该方案以"全链条改革、制度型开放、高水平创新"为核心骨架，系统构建起覆盖生物医药产业研 发、生产、流通、使用全周期的创新体系，每个关键词都精准破解产业发展痛点。 "一条链的改革，贯通6个方面18项政策集成。"省商务厅厅长司勇介绍，方案从增强研发创新能 力、提升审批服务水平、构建生产流通体系、完善采购使用政策、加大要素保障、守牢安全底线6个方 面，细化18项举措，核心目标是为国家探制度、为江苏赋动能、为企业解难题。 "全链条改革"立足优势精准破局。江苏生物医药产业规模占全国1/8，创新药获批数占1/3，均居全 国 ...

Group 1: AI and Biopharmaceutical Innovation - The establishment of the Jiangsu Provincial Artificial Intelligence Biopharmaceutical Technology Industry Research Institute aims to address critical challenges in the biopharmaceutical industry by integrating top talent and innovative collaboration mechanisms [1][2] - The research institute has gathered over 600 top scholars and more than 60 member organizations, focusing on transforming research outcomes from laboratories to production lines [1][2] - The institute has developed high-end facilities, including a 300kV cryo-electron microscope, to facilitate collaborative research among over 20 units, including universities and pharmaceutical companies [1] Group 2: Structural Challenges in Biopharmaceutical Industry - The research institute's development is driven by a dual approach of "expert leadership + mechanism innovation" to enhance the integration of industry, academia, and research [2] - The institute has achieved significant breakthroughs, such as the discovery of the complete structure of miRNA in human serum, which won the second prize in the 2024 National Natural Science Award [2] - Collaborations with companies like Huawei to create foundational models for drug development demonstrate the institute's commitment to providing technical support for the industry [2] Group 3: Integrated Circuit Industry Development - The successful launch of the first domestically produced 28nm electron beam measurement equipment by Wuxi Changdian Technology fills a gap in China's integrated circuit industry and enhances the autonomy of domestic chip manufacturing [3] - Wuxi has developed a collaborative ecosystem in the integrated circuit industry, with a cluster scale exceeding 250 billion yuan, ranking second nationally in output value [3] - The integration of technological innovation and equipment development has strengthened the competitiveness of companies in the global integrated circuit packaging and testing sector [3] Group 4: Technology and Industry Integration - The organization of industry-academia-research cooperation conferences aims to facilitate seamless connections between innovation chains and industry chains, accelerating the transformation of scientific achievements into productive forces [4] - Jiangsu Province has produced over 200 landmark achievements in industrial technology innovation, primarily in fields such as artificial intelligence, biopharmaceuticals, integrated circuits, and new materials [4]

Group 1 - The core viewpoint of the articles emphasizes the integration of AI in the biopharmaceutical industry, highlighting its potential to enhance efficiency, precision, and safety in drug development [1][2][4] - The global biopharmaceutical R&D faces challenges such as a 10-year development cycle, $1 billion investment, and less than 10% success rate, which AI is positioned to address through advanced data processing and predictive modeling [2][3] - Zhejiang University’s Intelligent Innovation Drug Research Institute has successfully incubated 7 companies and undertaken over 140 projects, addressing more than 200 critical issues faced by enterprises [2][4] Group 2 - Derui Zhiyuan, a key biopharmaceutical company in Qiantang, utilizes AI to reconstruct drug development pathways, significantly reducing the time and cost associated with identifying effective drug candidates [3][4] - Qiantang has established a robust biopharmaceutical ecosystem with over 1,800 companies and more than 500 high-end talents, including major global pharmaceutical firms and "quasi-unicorn" enterprises [4][5] - Pfizer's Smart Medical Innovation Center has been established in Qiantang, focusing on innovative digital solutions and improving patient quality of life, leveraging the region's strong digital and innovative capabilities [5][6]

Core Viewpoint - The 2025 World Artificial Intelligence Conference (WAIC) in Shanghai highlighted the significant role of AI in accelerating drug development and transforming the healthcare ecosystem, with a focus on innovation in the pharmaceutical industry [1][4]. Industry Insights - AI technology is rapidly evolving, enabling faster analysis of vast medical data, predicting drug efficacy, and shortening drug development cycles while reducing costs [1][4]. - The global pharmaceutical landscape is undergoing a transformation, with multinational companies increasingly sourcing innovative drugs from China, driven by supportive domestic policies and steady clinical advancements [1][4]. - The innovative drug sector has shown strong performance, with the Wind Innovation Drug Index rising by 48.51% and the Hong Kong Innovation Drug Index increasing by 104.51% as of July 31, 2025 [3]. Company Performance - The performance of the Noan Selected Value Mixed Fund has been notable, with a net value growth rate of 61.88% over the past six months, significantly outperforming its benchmark of 5.74% [3]. - The fund's strategy has focused on the undervaluation of the pharmaceutical sector, with a balanced investment approach in both Hong Kong and A-share markets [3][4]. - The establishment of the "Technology Group" by Noan Fund in 2020 reflects a proactive approach to building a diverse product matrix in the technology investment space [4]. Technological Advancements - Modern surgical robots are enhancing surgical precision by analyzing real-time data and providing feedback, which reduces risks and improves success rates [2]. - The rise of remote surgery, facilitated by 5G/6G networks, allows surgeons to operate on patients from thousands of kilometers away, improving access to healthcare in remote areas [2].

Core Insights - The article highlights the rapid advancements in AI-driven drug development in Hangzhou, particularly in the Qiantang (New) District, which is becoming a hub for the integration of AI and biomedicine [4][6][8] Group 1: AI in Drug Development - Derui Zhiyao's first AI-designed oral small molecule drug, MDR-001, has successfully entered clinical trials, offering new treatment options for overweight patients [4] - The company has developed a one-stop drug research and development platform, Molecule Pro™, which significantly reduces the time and cost of drug development by 50% and saves 1.5 to 3 years compared to traditional methods [6][7] - The Zhejiang University Intelligent Innovation Drug Research Institute has been instrumental in supporting local pharmaceutical companies with AI technology, leading to the incubation of seven drug companies in the Qiantang area [7][8] Group 2: Industry Growth and Investment - Qiantang District has established a comprehensive ecosystem for biomedicine, including preclinical research, clinical trial platforms, and full-chain industrialization processes [9] - The district's industrial fund has exceeded 45 billion yuan, with investments in 266 companies, including 71 unicorns, showcasing strong financial backing for the biomedicine sector [9] - Recent discussions at the Zhejiang Provincial High-level Talent Conference highlighted the potential of AI in transforming biomedical understanding and practices, indicating a forward-looking approach to industry development [8][9]

Group 1: Government Investment Fund Regulations - Gansu Province has issued guidelines to strictly control the establishment of government investment funds, emphasizing that these funds should not be set up for the purpose of attracting investment [2][3] - The guidelines promote the optimization and integration of existing funds, with a focus on unified management and avoiding duplication in the same industry or sector [2][3] - The policy reflects a shift from broad capital attraction to a focus on operational efficiency and quality in industry cultivation, aiming to leverage government investment funds for better industry guidance [3] Group 2: Private Equity Market Developments - Goldman Sachs Asset Management is seeking to raise over $14.2 billion for its new S Fund, indicating strong interest in the secondary private equity market [4] - The secondary market is expected to see a total trading volume of $185 billion by 2025, driven by liquidity challenges faced by many limited partners (LPs) [4] - Major firms like Blackstone and Carlyle are also actively engaging in the secondary market, highlighting its importance as an exit channel for private equity investments [4] Group 3: Venture Capital Innovations - Junlian Capital has launched Beijing's first technology innovation bond with a registered scale of 500 million yuan, aimed at supporting long-term investments in technology [5][6] - The introduction of the "technology board" in the bond market is expected to enhance funding channels for venture capital institutions, facilitating investments in early-stage and hard technology [5][6] - The successful issuance of technology innovation bonds by firms like Dongfang Fuhai indicates a growing trend in financing for venture capital institutions [6] Group 4: Corporate Investments - Zhongwei Company announced its participation in establishing a private equity fund with a target size of 1.5 billion yuan, focusing on the semiconductor and related strategic emerging sectors [7] - The fund plans to allocate over 80% of its investments to upstream and downstream enterprises in the integrated circuit industry, aligning with Zhongwei's core business [7] - This focused investment strategy aims to strengthen the supply chain and capture emerging technology trends while minimizing cross-industry risks [7] Group 5: AI and Biotechnology Investments - Insilico Medicine has completed a Series E financing round, raising approximately $123 million, reflecting strong investor interest in the AI-driven biopharmaceutical sector [8][9] - The investment highlights China's competitive edge in AI drug development, with local government and investment platforms strategically positioning themselves in this hard technology field [8][9] - The funding will support Insilico's efforts in drug discovery across various therapeutic areas, showcasing the integration of AI and automation in pharmaceutical innovation [8][9] Group 6: Smart Manufacturing Investments - Xiaomi has invested in Danikel Automation Technology, setting a record for single financing in the automatic feeding and intelligent tightening sector [9] - This investment is part of Xiaomi's broader strategy to deepen its involvement in smart manufacturing, providing technological synergies for its automotive business [9] - The record-breaking financing reflects strong market expectations for domestic high-end equipment replacement opportunities [9] Group 7: AI Infrastructure Investments - Alibaba Cloud has led a multi-million yuan Series A financing round for SiliconFlow, a company focused on general artificial intelligence infrastructure [10][11] - SiliconFlow aims to address high AI computing costs with innovative technologies, positioning itself as a key player in the AI industry [10][11] - The investment underscores the growing competition in AI infrastructure and the strategic importance of companies that can reduce AI deployment costs for enterprises [10][11]

Core Viewpoint - The establishment of the Yangtze River Delta AI Biomedicine Industry Alliance marks a significant step in exploring the integration of AI and biomedicine in the region [1][3]. Group 1: Alliance Formation - The alliance is led by the Wuxi Biomedicine Industry Association and involves institutions like Peking University and AstraZeneca, with 40 forward-looking AI medical companies joining as founding members [3]. - The core philosophy of the alliance is "innovation-driven, collaborative empowerment, and value sharing," aiming to integrate resources from government, hospitals, universities, pharmaceutical companies, and AI biomedicine enterprises [3]. Group 2: Functional Focus - The alliance will focus on the core needs of AI drug development and will perform five key functions: technology exchange, industry connection, policy empowerment, financial support, and brand building [3][4]. - It aims to facilitate deep penetration and innovative application of AI technology across the entire chain of biomedicine research, production, and application [3]. Group 3: Support for Member Companies - Member companies will benefit from a cross-border cooperation platform that provides diverse resource support from clinical, academic, and commercial sectors [4]. - The alliance will regularly organize AI technology training, publish industry white papers, and host international academic exchange activities to enhance the technical competitiveness of member companies [4]. Group 4: Conference Highlights - The 2025 Taihu Bay Life Health Future Conference focuses on themes such as "AI empowering pharmaceutical innovation" and aims to create a one-stop ecological cooperation platform for research, production, sales, and finance [5]. - New innovation centers and policies to support the biomedicine industry in Wuxi were unveiled during the conference, injecting new momentum into local biomedicine innovation [5].

Group 1: Event Overview - The "AI Empowering the Biopharmaceutical Industry Salon" was successfully held on May 8, 2025, in Shanghai, focusing on the innovative applications of AI technology in drug development and manufacturing [1] - The event gathered industry leaders, technical experts, and representatives from well-known companies for in-depth discussions and site visits [1] Group 2: Strategic Missions and Directions - The Shanghai Biopharmaceutical Industry Association outlined three strategic missions: building a collaborative innovation platform, fostering cross-industry ecosystems, and creating a global innovation hub [2] - Three key focus areas for industry development were proposed: technological innovation, application implementation, and regulatory support [2] Group 3: Industry Ecosystem and Investment - The Lingang Life Bay has established itself as a global biopharmaceutical innovation hub, attracting over 200 companies and forming three major industry clusters: biopharmaceuticals, high-end medical devices, and CRO/CDMO [3] - The Lingang Life Bay Fund promotes the deep integration of AI and healthcare through a unique "capital + service + platform" model [3] Group 4: AI Applications and Case Studies - Various experts shared insights on AI's role in pharmaceutical manufacturing, including digital transformation and energy-efficient solutions [5][6] - A roundtable discussion addressed challenges and opportunities in integrating AI throughout the drug development process, from laboratories to production [6] Group 5: Company Spotlight - Junshi Biosciences, established in 2012, is a global biopharmaceutical company with a total production capacity of 46,500 liters, expandable to 120,000 liters [7] - The company aims to provide accessible treatment options globally and has implemented AI-driven systems that improved production efficiency by 20% [7] Group 6: Future Outlook - The salon emphasized the importance of AI in the biopharmaceutical sector and the need for continuous industry collaboration to enhance China's competitive position in global markets [8]